Dr. Daniel Becker, MD
Neurology (Neurology Physician)
1447 York Rd Ste 508
Lutherville, MD 21093
Who else practices at this address →
Baltimore County includes dental (23% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 25
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 332
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
MD license D0066385 -
Spinal Cord Injury Medicine Physician
MD license D0066385
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Johns Hopkins Hospital, the Baltimore, MD
- Wellspan York Hospital York, PA
- Johns Hopkins Bayview Medical Center Baltimore, MD
- Gettysburg Hospital Gettysburg, PA
Medical groups
- Johns Hopkins University (2,909 clinicians)
- International Neurorehabilitation Institute (3 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 332
- Services billed
- 129,627
- Patients’ average age
- 68
| Service | Times | Patients |
|---|---|---|
| Injection, ocrelizumab, 1 mg | 84,000 | 80 |
| Continuous intraoperative neurophysiology monitoring, from outside the operating room (remote or nearby), per patient, (attention directed exclusively to one patient) each 15 minutes (list in addition to primary procedure) | 505 | 42 |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 442 | 93 |
| Established patient office or other outpatient visit, 40-54 minutes | 412 | 174 |
| Administration of chemotherapy into vein, 1 hour or less | 247 | 96 |
| Administration of psychological or neuropsychological test by technician, each additional 30 minutes | 237 | 114 |
| Administration of chemotherapy into vein, each additional hour | 235 | 92 |
| Testing of nerve-muscle junction | 200 | 76 |
| Imaging of optic nerve | 118 | 118 |
| Evaluation of neuropsychological test, first hour | 114 | 113 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Baclofen Other prescribers in Lutherville, MD | 148 |
| Dalfampridine Er (dalfampridine) | 71 |
| Teriflunomide | 65 |
| Gabapentin Other prescribers in Lutherville, MD | 55 |
| Aubagio (teriflunomide) | 54 |
| Copaxone (glatiramer acetate) | 37 |
| Zeposia (ozanimod hydrochloride) | 32 |
| Modafinil Other prescribers in Lutherville, MD | 27 |
| Botox (onabotulinumtoxina) | 20 |
| Amitriptyline Hcl Other prescribers in Lutherville, MD | 18 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 27 companies reported 362 payments worth $164,667 in total to this clinician.
| Vanda Pharmaceuticals Inc. | $72,105 |
|---|---|
| Amgen Inc. | $28,882 |
| Eisai Inc. | $25,970 |
| Tg Therapeutics, Inc. | $22,072 |
| Genzyme Corporation | $6,193 |
| E.r. Squibb & Sons, L.l.c. | $5,845 |
| Genentech USA, Inc. | $665 |
| EMD Serono, Inc. | $527 |
| Compensation for services other than consulting (speaking, faculty) | $107,085 |
|---|---|
| Travel and Lodging | $21,477 |
| Speaking at a medical education program | $18,723 |
| Food and Beverage | $9,048 |
| Consulting Fee | $8,259 |
| Education | $76.99 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. Jun 4, 2025 | Compensation for services other than consulting (speaking, faculty) PONVORY · MULTIPLE SCLEROSIS | $5,063 |
| Vanda Pharmaceuticals Inc. Aug 21, 2025 | Compensation for services other than consulting (speaking, faculty) PONVORY · MULTIPLE SCLEROSIS | $5,063 |
| Vanda Pharmaceuticals Inc. Aug 22, 2025 | Compensation for services other than consulting (speaking, faculty) PONVORY · MULTIPLE SCLEROSIS | $5,063 |
| Vanda Pharmaceuticals Inc. Aug 27, 2025 | Compensation for services other than consulting (speaking, faculty) PONVORY · MULTIPLE SCLEROSIS | $5,063 |
| Vanda Pharmaceuticals Inc. Oct 1, 2025 | Compensation for services other than consulting (speaking, faculty) PONVORY · MULTIPLE SCLEROSIS | $5,063 |
| Tg Therapeutics, Inc. Apr 26, 2025 | Compensation for services other than consulting (speaking, faculty) BRIUMVI · Immunology | $4,650 |
| Vanda Pharmaceuticals Inc. Dec 16, 2025 | Compensation for services other than consulting (speaking, faculty) PONVORY · MULTIPLE SCLEROSIS | $4,388 |
| Vanda Pharmaceuticals Inc. Feb 25, 2025 | Compensation for services other than consulting (speaking, faculty) PONVORY · MULTIPLE SCLEROSIS | $4,388 |
| Vanda Pharmaceuticals Inc. Mar 11, 2025 | Compensation for services other than consulting (speaking, faculty) PONVORY · MULTIPLE SCLEROSIS | $4,388 |
| Vanda Pharmaceuticals Inc. Nov 13, 2025 | Compensation for services other than consulting (speaking, faculty) PONVORY · MULTIPLE SCLEROSIS | $4,388 |
All 96 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Eisai Inc. Dec 22, 2025 | Consulting Fee Leqembi · Neurology | $110 |
| Vanda Pharmaceuticals Inc. Dec 16, 2025 | Compensation for services other than consulting (speaking, faculty) PONVORY · MULTIPLE SCLEROSIS | $4,388 |
| Vanda Pharmaceuticals Inc. Dec 16, 2025 | Compensation for services other than consulting (speaking, faculty) PONVORY · MULTIPLE SCLEROSIS | $2,700 |
| Vanda Pharmaceuticals Inc. Dec 16, 2025 | Travel and Lodging PONVORY · MULTIPLE SCLEROSIS · travel to CINCINNATI, OH | $478 |
| Vanda Pharmaceuticals Inc. Dec 16, 2025 | Travel and Lodging PONVORY · MULTIPLE SCLEROSIS · travel to DAYTON, OH | $478 |
| Vanda Pharmaceuticals Inc. Dec 16, 2025 | Travel and Lodging PONVORY · MULTIPLE SCLEROSIS · travel to CINCINNATI, OH | $225 |
| Vanda Pharmaceuticals Inc. Dec 16, 2025 | Travel and Lodging PONVORY · MULTIPLE SCLEROSIS · travel to CINCINNATI, OH | $110 |
| Vanda Pharmaceuticals Inc. Dec 16, 2025 | Travel and Lodging PONVORY · MULTIPLE SCLEROSIS · travel to DAYTON, OH | $110 |
| Janssen Biotech, Inc. Dec 12, 2025 | Education in-kind | $76.99 |
| Vanda Pharmaceuticals Inc. Dec 2, 2025 | Compensation for services other than consulting (speaking, faculty) PONVORY · MULTIPLE SCLEROSIS | $4,050 |
| Vanda Pharmaceuticals Inc. Dec 2, 2025 | Travel and Lodging PONVORY · MULTIPLE SCLEROSIS · travel to FULTON, MD | $40.60 |
| Eisai Inc. Nov 19, 2025 | Speaking at a medical education program Leqembi · Neurology | $1,600 |
| Eisai Inc. Nov 19, 2025 | Speaking at a medical education program Leqembi · Neurology | $640 |
| Vanda Pharmaceuticals Inc. Nov 13, 2025 | Compensation for services other than consulting (speaking, faculty) PONVORY · MULTIPLE SCLEROSIS | $4,388 |
| Vanda Pharmaceuticals Inc. Nov 13, 2025 | Travel and Lodging PONVORY · MULTIPLE SCLEROSIS · travel to LOUISVILLE, KY | $1,496 |
| Vanda Pharmaceuticals Inc. Nov 13, 2025 | Travel and Lodging PONVORY · MULTIPLE SCLEROSIS · travel to LOUISVILLE, KY | $224 |
| Vanda Pharmaceuticals Inc. Nov 13, 2025 | Travel and Lodging PONVORY · MULTIPLE SCLEROSIS · travel to LOUISVILLE, KY | $150 |
| Tg Therapeutics, Inc. Nov 12, 2025 | Compensation for services other than consulting (speaking, faculty) BRIUMVI · Immunology | $465 |
| Eisai Inc. Nov 11, 2025 | Consulting Fee Leqembi · Neurology | $1,600 |
| Amgen Inc. Nov 6, 2025 | Compensation for services other than consulting (speaking, faculty) UPLIZNA · Inflammation/Rare Disease | $3,300 |
| Tg Therapeutics, Inc. Nov 5, 2025 | Compensation for services other than consulting (speaking, faculty) BRIUMVI · Immunology | $3,713 |
| Eisai Inc. Oct 30, 2025 | Travel and Lodging Leqembi · Neurology · travel to Mechanicsville, MD | $934 |
| Eisai Inc. Oct 27, 2025 | Speaking at a medical education program Leqembi · Neurology | $1,920 |
| Eisai Inc. Oct 27, 2025 | Speaking at a medical education program Leqembi · Neurology | $1,600 |
| Eisai Inc. Oct 13, 2025 | Speaking at a medical education program Leqembi · Neurology | $1,600 |
| Eisai Inc. Oct 13, 2025 | Speaking at a medical education program Leqembi · Neurology | $640 |
| E.r. Squibb & Sons, L.l.c. Oct 6, 2025 | Compensation for services other than consulting (speaking, faculty) ZEPOSIA · Neuroscience | $2,900 |
| Vanda Pharmaceuticals Inc. Oct 1, 2025 | Compensation for services other than consulting (speaking, faculty) PONVORY · MULTIPLE SCLEROSIS | $5,063 |
| Vanda Pharmaceuticals Inc. Oct 1, 2025 | Travel and Lodging PONVORY · MULTIPLE SCLEROSIS · travel to GREENSBURG, PA | $1,236 |
| E.r. Squibb & Sons, L.l.c. Sep 17, 2025 | Travel and Lodging ZEPOSIA · Neuroscience · travel to Elkton, MD | $625 |
| Tg Therapeutics, Inc. Sep 10, 2025 | Compensation for services other than consulting (speaking, faculty) BRIUMVI · Immunology | $233 |
| Vanda Pharmaceuticals Inc. Aug 28, 2025 | Travel and Lodging PONVORY · MULTIPLE SCLEROSIS · travel to DETROIT, MI | $289 |
| Vanda Pharmaceuticals Inc. Aug 28, 2025 | Travel and Lodging PONVORY · MULTIPLE SCLEROSIS · travel to DETROIT, MI | $236 |
| Vanda Pharmaceuticals Inc. Aug 27, 2025 | Compensation for services other than consulting (speaking, faculty) PONVORY · MULTIPLE SCLEROSIS | $5,063 |
| Vanda Pharmaceuticals Inc. Aug 27, 2025 | Travel and Lodging PONVORY · MULTIPLE SCLEROSIS · travel to BIRMINGHAM, MI | $289 |
| Vanda Pharmaceuticals Inc. Aug 27, 2025 | Travel and Lodging PONVORY · MULTIPLE SCLEROSIS · travel to BIRMINGHAM, MI | $236 |
| Vanda Pharmaceuticals Inc. Aug 22, 2025 | Compensation for services other than consulting (speaking, faculty) PONVORY · MULTIPLE SCLEROSIS | $5,063 |
| Amgen Inc. Aug 22, 2025 | Compensation for services other than consulting (speaking, faculty) UPLIZNA · Inflammation/Rare Disease | $3,300 |
| Amgen Inc. Aug 22, 2025 | Compensation for services other than consulting (speaking, faculty) UPLIZNA · Inflammation/Rare Disease | $2,200 |
| Vanda Pharmaceuticals Inc. Aug 22, 2025 | Travel and Lodging PONVORY · MULTIPLE SCLEROSIS · travel to WINCHESTER, VA | $194 |
| Vanda Pharmaceuticals Inc. Aug 21, 2025 | Compensation for services other than consulting (speaking, faculty) PONVORY · MULTIPLE SCLEROSIS | $5,063 |
| Vanda Pharmaceuticals Inc. Aug 21, 2025 | Travel and Lodging PONVORY · MULTIPLE SCLEROSIS · travel to KALAMAZOO, MI | $1,062 |
| Eisai Inc. Aug 21, 2025 | Travel and Lodging Leqembi · Neurology · travel to Harrisonburg, VA | $601 |
| Vanda Pharmaceuticals Inc. Aug 21, 2025 | Travel and Lodging PONVORY · MULTIPLE SCLEROSIS · travel to KALAMAZOO, MI | $148 |
| Amgen Inc. Aug 20, 2025 | Compensation for services other than consulting (speaking, faculty) UPLIZNA · Inflammation/Rare Disease | $3,300 |
| Amgen Inc. Aug 20, 2025 | Compensation for services other than consulting (speaking, faculty) UPLIZNA · Inflammation/Rare Disease | $3,300 |
| Eisai Inc. Aug 20, 2025 | Speaking at a medical education program Leqembi · Neurology | $1,600 |
| Eisai Inc. Aug 20, 2025 | Speaking at a medical education program Leqembi · Neurology | $640 |
| Tg Therapeutics, Inc. Aug 11, 2025 | Compensation for services other than consulting (speaking, faculty) BRIUMVI · Immunology | $3,713 |
| Amgen Inc. Aug 9, 2025 | Travel and Lodging UPLIZNA · Inflammation/Rare Disease · travel to WHEAT RIDGE, CO · in-kind | $994 |
| Amgen Inc. Jul 15, 2025 | Travel and Lodging UPLIZNA · Inflammation/Rare Disease · travel to WHEAT RIDGE, CO · in-kind | $487 |
| Eisai Inc. Jun 29, 2025 | Travel and Lodging Leqembi · Neurology · travel to Harrisonburg, VA | $734 |
| Amgen Inc. Jun 25, 2025 | Compensation for services other than consulting (speaking, faculty) UPLIZNA · Inflammation/Rare Disease | $3,300 |
| Eisai Inc. Jun 24, 2025 | Speaking at a medical education program Leqembi · Neurology | $1,463 |
| Eisai Inc. Jun 24, 2025 | Speaking at a medical education program Leqembi · Neurology | $585 |
| Vanda Pharmaceuticals Inc. Jun 4, 2025 | Compensation for services other than consulting (speaking, faculty) PONVORY · MULTIPLE SCLEROSIS | $5,063 |
| Vanda Pharmaceuticals Inc. Jun 4, 2025 | Travel and Lodging PONVORY · MULTIPLE SCLEROSIS · travel to EVANSVILLE, IN | $1,579 |
| Vanda Pharmaceuticals Inc. Jun 4, 2025 | Travel and Lodging PONVORY · MULTIPLE SCLEROSIS · travel to EVANSVILLE, IN | $146 |
| Vanda Pharmaceuticals Inc. Jun 4, 2025 | Travel and Lodging PONVORY · MULTIPLE SCLEROSIS · travel to EVANSVILLE, IN | $66.40 |
| Biogen, Inc. May 14, 2025 | Consulting Fee TYSABRI · Neurology | $150 |
| Eisai Inc. May 9, 2025 | Consulting Fee Leqembi · Neurology | $183 |
| Eisai Inc. May 9, 2025 | Consulting Fee Leqembi · Neurology | $110 |
| Tg Therapeutics, Inc. Apr 28, 2025 | Compensation for services other than consulting (speaking, faculty) BRIUMVI · Immunology | $3,713 |
| Tg Therapeutics, Inc. Apr 26, 2025 | Compensation for services other than consulting (speaking, faculty) BRIUMVI · Immunology | $4,650 |
| Tg Therapeutics, Inc. Apr 25, 2025 | Travel and Lodging BRIUMVI · Immunology · travel to Dallas, TX · in-kind | $373 |
| Tg Therapeutics, Inc. Apr 25, 2025 | Travel and Lodging BRIUMVI · Immunology · travel to Dallas, TX · in-kind | $316 |
| Genzyme Corporation Mar 27, 2025 | Consulting Fee | $3,954 |
| Genzyme Corporation Mar 27, 2025 | Consulting Fee | $1,977 |
| Alexion Pharmaceuticals, Inc. Mar 27, 2025 | Consulting Fee ULTOMIRIS · Rare Disease | $175 |
| Amgen Inc. Mar 21, 2025 | Compensation for services other than consulting (speaking, faculty) UPLIZNA · Inflammation/Rare Disease | $3,300 |
| E.r. Squibb & Sons, L.l.c. Mar 20, 2025 | Compensation for services other than consulting (speaking, faculty) ZEPOSIA · Neuroscience | $2,320 |
| Vanda Pharmaceuticals Inc. Mar 11, 2025 | Compensation for services other than consulting (speaking, faculty) PONVORY · MULTIPLE SCLEROSIS | $4,388 |
| Vanda Pharmaceuticals Inc. Mar 11, 2025 | Compensation for services other than consulting (speaking, faculty) PONVORY · MULTIPLE SCLEROSIS | $3,375 |
| Vanda Pharmaceuticals Inc. Mar 11, 2025 | Travel and Lodging PONVORY · MULTIPLE SCLEROSIS · travel to NOVI, MI | $2,700 |
| Vanda Pharmaceuticals Inc. Mar 11, 2025 | Travel and Lodging PONVORY · MULTIPLE SCLEROSIS · travel to TROY, MI | $737 |
| Vanda Pharmaceuticals Inc. Mar 11, 2025 | Travel and Lodging PONVORY · MULTIPLE SCLEROSIS · travel to CLINTON TOWNSHIP, MI | $136 |
| Vanda Pharmaceuticals Inc. Mar 11, 2025 | Travel and Lodging PONVORY · MULTIPLE SCLEROSIS · travel to TROY, MI | $136 |
| Vanda Pharmaceuticals Inc. Mar 11, 2025 | Travel and Lodging PONVORY · MULTIPLE SCLEROSIS · travel to NOVI, MI | $86.31 |
| Vanda Pharmaceuticals Inc. Mar 11, 2025 | Travel and Lodging PONVORY · MULTIPLE SCLEROSIS · travel to CLINTON TOWNSHIP, MI | $86.31 |
| Vanda Pharmaceuticals Inc. Mar 11, 2025 | Travel and Lodging PONVORY · MULTIPLE SCLEROSIS · travel to TROY, MI | $86.31 |
| Vanda Pharmaceuticals Inc. Feb 25, 2025 | Compensation for services other than consulting (speaking, faculty) PONVORY · MULTIPLE SCLEROSIS | $4,388 |
| Vanda Pharmaceuticals Inc. Feb 25, 2025 | Compensation for services other than consulting (speaking, faculty) PONVORY · MULTIPLE SCLEROSIS | $3,375 |
| Amgen Inc. Feb 25, 2025 | Compensation for services other than consulting (speaking, faculty) UPLIZNA · Inflammation/Rare Disease | $3,300 |
| Vanda Pharmaceuticals Inc. Feb 25, 2025 | Travel and Lodging PONVORY · MULTIPLE SCLEROSIS · travel to GREENFIELD, IN | $446 |
| Vanda Pharmaceuticals Inc. Feb 25, 2025 | Travel and Lodging PONVORY · MULTIPLE SCLEROSIS · travel to INDIANAPOLIS, IN | $446 |
| Vanda Pharmaceuticals Inc. Feb 25, 2025 | Travel and Lodging PONVORY · MULTIPLE SCLEROSIS · travel to INDIANAPOLIS, IN | $403 |
| Vanda Pharmaceuticals Inc. Feb 25, 2025 | Travel and Lodging PONVORY · MULTIPLE SCLEROSIS · travel to GREENFIELD, IN | $119 |
| Vanda Pharmaceuticals Inc. Feb 25, 2025 | Travel and Lodging PONVORY · MULTIPLE SCLEROSIS · travel to INDIANAPOLIS, IN | $119 |
| Tg Therapeutics, Inc. Feb 24, 2025 | Compensation for services other than consulting (speaking, faculty) BRIUMVI · Immunology | $3,713 |
| Tg Therapeutics, Inc. Feb 24, 2025 | Travel and Lodging BRIUMVI · Immunology · travel to Columbia, MD | $35.00 |
| Eisai Inc. Feb 21, 2025 | Travel and Lodging Leqembi · Neurology · travel to Harrisonburg, VA | $1,108 |
| Eisai Inc. Feb 20, 2025 | Speaking at a medical education program Leqembi · Neurology | $1,755 |
| Eisai Inc. Feb 20, 2025 | Speaking at a medical education program Leqembi · Neurology | $1,463 |
| Eisai Inc. Feb 7, 2025 | Travel and Lodging Leqembi · Neurology · travel to Hagerstown, MD | $974 |
| Eisai Inc. Feb 5, 2025 | Speaking at a medical education program Leqembi · Neurology | $1,755 |
| Eisai Inc. Feb 5, 2025 | Speaking at a medical education program Leqembi · Neurology | $1,463 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $94,507 in research payments for these studies, mostly to the institutions running them.
- Ocrelizumab PPMS High Dose Study
Genentech, Inc. - Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment
Roche Products Limited - A prospective, multicenter, observational, post-authorization safety study (PASS) to evaluate the long term safety profile of LEMTRADA (alemtuzumab) treatment in patients with relapsing forms of multiple sclerosis (RMS)
Genzyme Corporation - Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
Genzyme Corporation · Active, not recruiting · NCT06141473
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.